Cargando…

Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants

This cohort study investigates whether MUC16 variation could be a useful biomarker for immune checkpoint inhibitor (ICI) therapy.

Detalles Bibliográficos
Autores principales:	Yu, Yunfang, Lin, Dagui, Li, Anlin, Chen, Yongjian, Ou, Qiyun, Hu, Hai, Yao, Herui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292997/ https://www.ncbi.nlm.nih.gov/pubmed/32530468 http://dx.doi.org/10.1001/jamanetworkopen.2020.5837

Ejemplares similares

Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation
por: He, Zifan, et al.
Publicado: (2020)

Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020)

Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
por: Yu, Yunfang, et al.
Publicado: (2020)

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer: A Meta-analysis and Individual Patient–Level Analysis
por: Yu, Yunfang, et al.
Publicado: (2019)

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
por: Ou, Qiyun, et al.
Publicado: (2020)

Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer
por: Yu, Yunfang, et al.
Publicado: (2020)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Effect of prior cancer history on survival of patients with esophageal carcinoma: a propensity score matching, population-based study
por: Liu, Jingwen, et al.
Publicado: (2022)

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study
por: Ren, Wei, et al.
Publicado: (2022)

NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors
por: Meng, Xiang-Yu
Publicado: (2023)

A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma
por: Huang, Yunxi, et al.
Publicado: (2023)

Overexpression of MUC16 predicts favourable prognosis in MUC16-mutant cervical cancer related to immune response
por: Wang, Hao, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics–Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer
por: Yu, Yunfang, et al.
Publicado: (2020)

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy
por: Lin, Lili, et al.
Publicado: (2023)

Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study
por: Yu, Yunfang, et al.
Publicado: (2021)

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma
por: Ouyang, Wenhao, et al.
Publicado: (2022)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Immune checkpoint inhibitors: friend or foe for osteoporosis
por: Tang, Jun
Publicado: (2023)

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis
por: Yamamoto-Furusho, Jesús K., et al.
Publicado: (2015)

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng
por: Aizenbud, Lilach, et al.
Publicado: (2023)

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
por: Tan, Sean, et al.
Publicado: (2023)

Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)
por: Hanson, Ryan L., et al.
Publicado: (2016)

Comparison of the Transmembrane Mucins MUC1 and MUC16 in Epithelial Barrier Function
por: Gipson, Ilene K., et al.
Publicado: (2014)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
por: Li, Zhaoyi, et al.
Publicado: (2019)

Concentrations of MUC16 and MUC5AC using three tear collection methods
por: Ablamowicz, Anna F., et al.
Publicado: (2017)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Suppression of Toll-like Receptor-Mediated Innate Immune Responses at the Ocular Surface by the Membrane-associated Mucins MUC1 and MUC16
por: Menon, Balaraj B., et al.
Publicado: (2015)

Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer
por: Jain, Shruti, et al.
Publicado: (2022)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer
por: Liu, Yajing, et al.
Publicado: (2023)

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
por: Medrano, Chloé, et al.
Publicado: (2019)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
por: Xie, Ning, et al.
Publicado: (2020)

Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas
por: Jonckheere, Nicolas, et al.
Publicado: (2018)

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients
por: Liu, Bing, et al.
Publicado: (2022)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g7nfojpca1tvoa7ksfe7vpc1ba